Search

Author/Creator Pienkowski, T.

1. 1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Issue 3 (September 2015)

Authors:
Zielinski, C.C.; Lang, I.; Inbar, M.; Kahan, Z.; Greil, R.; Beslija, S.; Stemmer, S.M.; Zvirbule, Z.; Steger, G.G.; Melichar, B.; Pienkowski, T.; Sirbu, D.; Petruzelka, L.; Eniu, A.; Nisenbaum, B.; Dank, M.; Anghel, R.; Messinger, D.; Brodowicz, T.
Journal:
European journal of cancer
Issue:
Volume 51:Issue 3(2015:Feb.)
Page Start:
S263
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoSphere study. (April 2018)

Authors:
Triulzi, T.; Di Cosimo, S.; Bianchini, G.; Pienkowski, T.; Im, Y.H.; Bianchi, G.V.; De Cecco, L.; Tseng, L.M.; Liu, M.C.; Lluch, A.; Semiglazov, V.; De la Haba-Rodriguez, J.; Oh, D.Y.; Poirier, B.; Pedrini, J.L.; Valagussa, P.; Tagliabue, E.; Gianni, L.
Journal:
European journal of cancer
Issue:
Volume 92(2018)Supplement 3
Page Start:
S8
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search